Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:XENE - CA98420N1050 - Common Stock

40.74 USD
-0.84 (-2.02%)
Last: 1/15/2026, 4:30:03 PM
40.74 USD
0 (0%)
After Hours: 1/15/2026, 4:30:03 PM
Fundamental Rating

3

XENE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. XENE has a great financial health rating, but its profitability evaluates not so good. XENE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • XENE had negative earnings in the past year.
  • In the past year XENE has reported a negative cash flow from operations.
  • XENE had negative earnings in each of the past 5 years.
  • In the past 5 years XENE always reported negative operating cash flow.
XENE Yearly Net Income VS EBIT VS OCF VS FCFXENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • With a Return On Assets value of -50.40%, XENE perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
  • XENE has a better Return On Equity (-54.75%) than 64.39% of its industry peers.
Industry RankSector Rank
ROA -50.4%
ROE -54.75%
ROIC N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
XENE Yearly ROA, ROE, ROICXENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • XENE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XENE Yearly Profit, Operating, Gross MarginsXENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

8

2. Health

2.1 Basic Checks

  • XENE has more shares outstanding than it did 1 year ago.
  • XENE has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
XENE Yearly Shares OutstandingXENE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
XENE Yearly Total Debt VS Total AssetsXENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 36.30 indicates that XENE is not in any danger for bankruptcy at the moment.
  • XENE has a better Altman-Z score (36.30) than 94.70% of its industry peers.
  • XENE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 36.3
ROIC/WACCN/A
WACCN/A
XENE Yearly LT Debt VS Equity VS FCFXENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • XENE has a Current Ratio of 12.52. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 12.52, XENE belongs to the best of the industry, outperforming 87.69% of the companies in the same industry.
  • XENE has a Quick Ratio of 12.52. This indicates that XENE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of XENE (12.52) is better than 87.69% of its industry peers.
Industry RankSector Rank
Current Ratio 12.52
Quick Ratio 12.52
XENE Yearly Current Assets VS Current LiabilitesXENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for XENE have decreased strongly by -37.94% in the last year.
EPS 1Y (TTM)-37.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 13.39% on average over the next years. This is quite good.
  • Based on estimates for the next years, XENE will show a very strong growth in Revenue. The Revenue will grow by 371.18% on average per year.
EPS Next Y-43.23%
EPS Next 2Y-26.18%
EPS Next 3Y-15.14%
EPS Next 5Y13.39%
Revenue Next Year2460.65%
Revenue Next 2Y312.31%
Revenue Next 3Y570.79%
Revenue Next 5Y371.18%

3.3 Evolution

XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for XENE. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XENE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XENE Price Earnings VS Forward Price EarningsXENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XENE Per share dataXENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as XENE's earnings are expected to decrease with -15.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.18%
EPS Next 3Y-15.14%

More info and screens

0

5. Dividend

5.1 Amount

  • XENE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

XENON PHARMACEUTICALS INC

NASDAQ:XENE (1/15/2026, 4:30:03 PM)

After market: 40.74 0 (0%)

40.74

-0.84 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)02-25
Inst Owners111.55%
Inst Owner Change0.12%
Ins Owners0.08%
Ins Owner Change-4.33%
Market Cap3.15B
Revenue(TTM)7.50M
Net Income(TTM)-306.33M
Analysts86.92
Price Target56.41 (38.46%)
Short Float %7.49%
Short Ratio7.22
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.85%
Min EPS beat(2)-5.82%
Max EPS beat(2)2.13%
EPS beat(4)3
Avg EPS beat(4)2.84%
Min EPS beat(4)-5.82%
Max EPS beat(4)10.75%
EPS beat(8)6
Avg EPS beat(8)4.34%
EPS beat(12)9
Avg EPS beat(12)3.84%
EPS beat(16)10
Avg EPS beat(16)0.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.4%
PT rev (3m)1.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.87%
EPS NY rev (1m)0%
EPS NY rev (3m)0.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 419.78
P/FCF N/A
P/OCF N/A
P/B 5.63
P/tB 5.63
EV/EBITDA N/A
EPS(TTM)-3.89
EYN/A
EPS(NY)-4.81
Fwd EYN/A
FCF(TTM)-3.28
FCFYN/A
OCF(TTM)-3.26
OCFYN/A
SpS0.1
BVpS7.24
TBVpS7.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.4%
ROE -54.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.61%
ROA(5y)-18.62%
ROE(3y)-22.67%
ROE(5y)-19.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.28%
Cap/Sales 16.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.52
Quick Ratio 12.52
Altman-Z 36.3
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)190.35%
Cap/Depr(5y)241.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.98%
EPS Next Y-43.23%
EPS Next 2Y-26.18%
EPS Next 3Y-15.14%
EPS Next 5Y13.39%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year2460.65%
Revenue Next 2Y312.31%
Revenue Next 3Y570.79%
Revenue Next 5Y371.18%
EBIT growth 1Y-33.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.57%
EBIT Next 3Y-5.11%
EBIT Next 5Y12.46%
FCF growth 1Y-68.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-76.75%
OCF growth 3YN/A
OCF growth 5YN/A

XENON PHARMACEUTICALS INC / XENE FAQ

What is the ChartMill fundamental rating of XENON PHARMACEUTICALS INC (XENE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to XENE.


Can you provide the valuation status for XENON PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to XENON PHARMACEUTICALS INC (XENE). This can be considered as Overvalued.


Can you provide the profitability details for XENON PHARMACEUTICALS INC?

XENON PHARMACEUTICALS INC (XENE) has a profitability rating of 1 / 10.


How financially healthy is XENON PHARMACEUTICALS INC?

The financial health rating of XENON PHARMACEUTICALS INC (XENE) is 8 / 10.